Project ETNA-VTE-Europe – Non-Interventional Study on Edoxaban Treatmentin Routine Clinical Practice in Patientswith…

Basic data

Acronym:
ETNA-VTE-Europe
Title:
Non-Interventional Study on Edoxaban Treatmentin Routine Clinical Practice in Patientswith Venous Thromboembolism in Europe
Duration:
09/06/2016 to 31/12/2019
Abstract / short description:
Primary objective is the analysis of the overall symptomatic VTE recurrence rate during an overall observational period of 18 months in unselected patients with acute VTE treated with edoxaban.
The co-primary objective of this study is to collect real world safety data on bleeding events, drug related adverse events such as liver adverse events, and mortality (VTE-related and all-cause) in patients treated with edoxaban. Furthermore, safety analyses in pre-specified subpopulations such as patients with renal impairment and patients with hepatic impairment will be performed.
Secondary objective is to assess the effect of edoxaban on relevant patient outcomes as recurrence rate of symptomatic VTE during treatment, recurrence rate of symptomatic VTE after cessation of edoxaban treatment, hospitalisations, postthrombotic syndrome (PTS), persistence to therapy (rate of permanent discontinuation, duration of time on therapy, reasons for permanent discontinuation), patient/physician reported outcomes, health care utilization, resource use.
Keywords:
Edoxaban
Lixiana
VTE
Beinvenenthrombose
Thromboembolien

Staff

Managers

Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Internal Medicine Department III
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine

Funders

St-Prex, Switzerland
Help

will be deleted permanently. This cannot be undone.